What is JANX (JANX) stock price today?

JANX (JANX) is currently trading at $16.04, up 0.25% today.

What is JANX P/E ratio?

JANX's P/E ratio is -7.78. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is JANX return on equity (ROE)?

JANX's return on equity (ROE) is -11.91%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is JANX's market cap?

JANX has a market capitalization of $978.19M.

NASDAQ · Biotechnology

JANX (JANX) Stock

$16.04 +0.25% NASDAQ: JANX Healthcare

Valuation

Metric	Value
Price	$16.04
Market Cap	$978.19M
P/E Ratio	-7.78
P/B Ratio	0.91
P/S Ratio	39.59
EPS (TTM)	$-1.83
52-Week High	$35.34
52-Week Low	$12.12
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-11.91%
ROA	-11.31%
ROCE	-16.51%
Gross Margin	-1580.00%
Operating Margin	-1580.00%
Net Margin	-5.30%
Debt/Equity	0.02
Current Ratio	39.04

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$4.0M	$9.0M	$8.0M	$11.0M	$10.0M
Operating Profit	$-33.0M	$-67.0M	$-73.0M	$-99.0M	$-158.0M
Net Profit	$-33.0M	$-63.0M	$-58.0M	$-69.0M	$-114.0M
EPS	$-0.79	$-1.52	$-1.32	$-1.28	$-1.83
Op Margin	-905.4%	-779.0%	-902.9%	-933.6%	-1576.7%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$380.0M	$364.0M	$380.0M	$1.1B	$1.0B
Total Liabilities	$13.0M	$43.0M	$36.0M	$39.0M	$51.0M
Cash	$36.0M	$51.0M	$19.0M	$431.0M	$52.0M
Borrowings	$0	$25.0M	$25.0M	$23.0M	$22.0M

Latest News

Is Janux Therapeutics’ (JANX) Russell Index Exit Quietly Rewriting Its Investor Base and Story? Simply Wall St. · Jul 9, 2026 VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone Exec Edge · Jul 2, 2026 Is Janux Therapeutics, Inc. (JANX) Stock a Biotech Opportunity With Next-Generation Immunotherapy Potential? Insider Monkey · Jun 30, 2026 Akari Therapeutics Highlights 1st ASCO Abstract Acceptance IPO-Edge.com · May 28, 2026 VERAXA Biotech Secures $27.5M Financing, to Go Public Via SPAC Exec Edge · May 28, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-17.0M	$-43.0M	$-51.0M	$-44.0M	$-82.0M
Investing Cash Flow	$-342.0M	$52.0M	$-43.0M	$-258.0M	$-302.0M
Financing Cash Flow	$2.0M	$0	$3.0M	$15.0M	$0
Net Cash Flow	$29.0M	$16.0M	$-32.0M	$411.0M	$-378.0M
Free Cash Flow	$-18.0M	$-49.0M	$-52.0M	$-44.0M	$-83.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-9.17%
Quick Ratio	17.01
Interest Coverage	—
Return 1Y	-40.59%
Return 3Y	15.25%
Return 5Y	-41.10%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ABCL	$6.93	+6.13%	-5.91	$2.12B	0.00%
BHVN	$14.07	+3.19%	-6.11	$2.12B	0.00%
CLDX	$35.80	+0.63%	-7.84	$2.38B	0.00%
HRMY	$38.24	-1.39%	11.23	$2.21B	0.00%
IMNM	$23.22	+2.83%	-8.13	$2.22B	0.00%

About JANX

JANX is led by CEO David Alan Campbell, employs 91 people, headquartered in US, publicly traded since 2021.

JANX stock trades at $16.04 with a market capitalization of $978.19M. The stock is valued at a price-to-earnings (P/E) ratio of -7.78, price-to-book of 0.91, price-to-sales of 39.59. Over the past 52 weeks the stock has ranged between $12.12 and $35.34, and currently trades 54.6% below its 52-week high.

On profitability, JANX generates a return on equity (ROE) of -11.91%, return on capital employed of -16.51%, an operating margin of -1580.00%, a net profit margin of -5.30%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides